Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.

log into MY ENETS

ENETS Abstract Search

#994 Predictive Biomarkers of Response in Patients with Extrapulmonary Neuroendocrine Tumors (EPNET) Treated with Platin-based Chemotherapy

Introduction: EPNET, particularly advanced and Grade 3 (G3) tumors are often treated with chemotherapy. While many patients experience tumor response, those rarely live for more than two years. Predictive markers could potentially help us to tailor the best treatment for these patients (pts).

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: Rego J

Authors: Rego J, Medeiros R, Braghiroli M, Bezerra Neto J, Munhoz R,

Keywords: biomarker, neuroendocrine tumors,

#733 Analysis of Predictive Markers of Response to Chemotherapy in Microdissected Components of Mixed Neuroendocrine/non-Neuroendocrine Carcinomas

Introduction: Mixed neuroendocrine (NE)/non-NE carcinomas lack pathological or molecular prognostic or predictive markers.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author: Volante M

Authors: Volante M, Monica V, Birocco N, Daniele L, Busso S,

Keywords: mixed carcinomas, molecular analysis, prognosis ,

#364 Platinum-based chemotherapy in patients with advanced neuroendocrine carcinomas: an Italian retrospective multicenter analysis

Introduction: Conventional chemotherapy has not yet a well defined role in well/moderately differentiated (WD) neuroendocrine carcinomas (NECs).

Conference:

Presenting Author:

Authors: SPADA F, SCARABELLI L, LORIZZO K, PELOSI G, BARBERIS M,

Keywords: neuroendocrine, ERCC1, Ki 67 ,

#144 Oxaliplatin-based chemotherapy in patients with advanced neuroendocrine carcinoma: an Italian retrospective multicenter analysis

Introduction: Conventional chemotherapy does not have a well-defined role in well/moderately differentiated (WD) neuroendocrine carcinomas (NECs). Various regimens were evaluated. Cisplatin or carboplatin combined with etoposide are usually indicated in poorly differentiated (PD) NECs. Some evidence exists for oxaliplatin activity in WD and PD NECs, combined with capecitabine or gemcitabine.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author: Spada F

Authors: Spada F, Nobili E, Ricasoli M, Scarabelli L, Pelosi G,

Keywords: neuroendocrine tumors, oxaliplatin, ERCC1, Ki 67 ,